Bulk Pharmaceutical API Sources for dofetilide

Bulk Pharmaceutical API Sources for dofetilide

Vendor	Vendor Homepage	Vendor Sku	API Url
NIH Clinical Collection		SAM001246621
Hangzhou Trylead Chemical Technology		TL8000450
NovoSeek		71329

Dofetilide API Sourcing: Key Manufacturers and Supply Chain Dynamics

Last updated: February 19, 2026

This report identifies primary bulk active pharmaceutical ingredient (API) manufacturers for dofetilide, analyzes supply chain characteristics, and outlines regulatory considerations relevant to sourcing this critical antiarrhythmic medication. Dofetilide is a class III antiarrhythmic agent used to maintain normal sinus rhythm in patients with atrial fibrillation or atrial flutter.

Who are the Primary Manufacturers of Dofetilide API?

Several manufacturers globally supply bulk dofetilide API. Key players include both established generic API producers and specialized chemical synthesis companies.

• Teva Pharmaceutical Industries Ltd. is a significant supplier, leveraging its extensive manufacturing network and experience in producing complex APIs. Teva's API division is a major global player in the generic pharmaceutical space.
• Hetero Drugs Limited is another prominent Indian manufacturer with a broad API portfolio, including cardiovascular drugs. Their capacity and quality control systems support the production of dofetilide at scale.
• Lupin Limited, also an Indian pharmaceutical company, is recognized for its API manufacturing capabilities. Lupin's focus on complex generics and intermediates positions them as a reliable source.
• Divi's Laboratories Limited is a leading Indian API manufacturer known for its contract manufacturing and proprietary product development. Their expertise in complex chemical synthesis is a core strength.
• Nectar Lifesciences Limited is an Indian pharmaceutical company that manufactures and markets APIs. They are involved in the production of various therapeutic segments, including cardiovascular agents.

This list represents some of the most consistently reported and accessible API suppliers. The market is dynamic, and other regional or specialized manufacturers may also be active.

What are the Key Characteristics of the Dofetilide API Supply Chain?

The dofetilide API supply chain is characterized by a focus on stringent quality control, regulatory compliance, and geographical concentration.

• Geographical Concentration: A significant portion of dofetilide API manufacturing is concentrated in India and, to a lesser extent, China. This concentration offers economies of scale but also presents potential supply chain risks related to geopolitical events, natural disasters, or regional regulatory changes.
• Quality and Regulatory Scrutiny: Dofetilide is a potent drug with a narrow therapeutic index, necessitating extremely high purity and consistent quality. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose strict Good Manufacturing Practice (GMP) standards on API production. Manufacturers must maintain Drug Master Files (DMFs) or equivalent regulatory submissions.
• Complexity of Synthesis: The chemical synthesis of dofetilide involves multiple steps and requires specialized expertise and equipment. This complexity limits the number of manufacturers capable of producing the API to the required pharmaceutical grade.
• Patent Landscape: While the primary patents for dofetilide itself have expired, patents related to specific polymorphs, manufacturing processes, or formulations can still influence market access and supplier choice. Analysts must monitor patent filings and litigation to understand potential disruptions or exclusive manufacturing rights.
• Demand Drivers: The demand for dofetilide API is directly linked to the prescription rates for dofetilide-containing finished dosage forms. Market forecasts for atrial fibrillation treatments and the competitive landscape of antiarrhythmic drugs influence long-term API demand.
• Pricing: API pricing is subject to raw material costs, manufacturing complexity, regulatory compliance overhead, and market competition. Fluctuations in these factors can impact the cost of dofetilide API.

Dofetilide API Supply Chain Factors

Factor	Description	Impact on Sourcing
Manufacturing Location	Primarily India and China.	Risk concentration, but also access to a large manufacturing base. Requires robust supplier audits and risk mitigation strategies.
Regulatory Compliance	Strict adherence to GMP, FDA, EMA, and other global regulatory standards. DMF submission and ongoing updates are mandatory.	Limits the pool of qualified suppliers. Requires thorough due diligence on manufacturer's regulatory history and inspection readiness.
Synthetic Complexity	Multi-step chemical synthesis requiring specialized knowledge and infrastructure.	Creates barriers to entry for new manufacturers. Potential for supply disruptions if a key step has limited capacity.
Quality Assurance	High purity requirements, control of impurities and enantiomeric excess are critical.	Demands rigorous analytical testing, validated methods, and consistent batch-to-batch quality.
Intellectual Property	Expired compound patents, but potential for process or formulation patents.	Must assess IP landscape to avoid infringement and ensure freedom to operate for finished product manufacturers.
Cost Structure	Influenced by raw material availability, energy costs, labor, and regulatory burden.	Requires competitive analysis and negotiation strategies based on market dynamics and supplier capabilities.
Supply Chain Resilience	Geopolitical stability, trade agreements, logistics infrastructure, and supplier financial health.	Diversification of suppliers and geographical regions can mitigate risks.

What are the Regulatory Considerations for Dofetilide API Sourcing?

Sourcing dofetilide API involves navigating a complex regulatory environment designed to ensure drug safety and efficacy.

• Drug Master Files (DMFs): Manufacturers must maintain and submit DMFs to regulatory agencies like the FDA. These confidential documents provide detailed information about the API manufacturing process, quality control, and facilities. Finished dosage form manufacturers reference these DMFs in their drug applications (e.g., ANDAs in the US).
• Good Manufacturing Practices (GMP): All API manufacturing sites must comply with cGMP regulations. This includes rigorous controls over personnel, facilities, equipment, raw materials, production processes, laboratory testing, and documentation.
• Site Inspections: Regulatory agencies conduct routine inspections of API manufacturing facilities to verify GMP compliance. Successful inspection outcomes are critical for maintaining supply authorization.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are globally recognized standards for API manufacturing.
• Impurity Profiling: Detailed characterization and control of process-related impurities and degradation products are paramount. Manufacturers must demonstrate control over genotoxic impurities and other potentially harmful substances to extremely low levels.
• Stability Studies: Comprehensive stability data demonstrating the API's shelf-life under various storage conditions is required. This data supports the expiration dating of the API.
• Import/Export Regulations: Sourcing APIs across international borders involves compliance with import and export regulations, including customs declarations, tariffs, and any specific country requirements for pharmaceutical ingredients.
• Pharmacopoeial Standards: API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).

Dofetilide API Sourcing: Key Considerations

When evaluating potential dofetilide API suppliers, strategic considerations extend beyond price and immediate availability.

• Supplier Audit and Qualification: A thorough audit process is essential. This includes on-site assessments of manufacturing facilities, quality management systems, analytical capabilities, and regulatory compliance history. Supplier qualification should assess not only current compliance but also their capacity for continuous improvement and proactive risk management.
• Supply Chain Transparency and Traceability: Understanding the full scope of the supply chain, including the sourcing of critical raw materials and intermediates, is vital. This enhances transparency and allows for better identification and mitigation of potential upstream risks.
• Contingency Planning: Developing robust contingency plans for supply disruptions is critical. This may involve qualifying multiple API suppliers, maintaining safety stock, and establishing strong relationships with logistics providers.
• Intellectual Property Review: A comprehensive review of the intellectual property landscape surrounding dofetilide API manufacturing processes is necessary to ensure freedom to operate and avoid potential patent infringements.
• Long-Term Partnership Potential: For critical APIs like dofetilide, fostering long-term partnerships with reliable suppliers is often more beneficial than transactional sourcing. This can lead to better pricing, preferential allocation during shortages, and collaborative problem-solving.
• Regulatory Support: The chosen API supplier must provide comprehensive regulatory support, including timely updates to DMFs, responses to regulatory queries, and assistance during facility inspections.

Key Takeaways

• Primary dofetilide API manufacturing is concentrated among a limited number of established generic API producers, predominantly in India, such as Teva, Hetero, Lupin, Divi's Laboratories, and Nectar Lifesciences.
• The supply chain is governed by stringent regulatory requirements, including GMP, DMF submissions, and rigorous quality control, necessitating thorough due diligence on potential suppliers.
• Key considerations for sourcing include geographical concentration risks, synthetic complexity, the need for comprehensive regulatory support, and the strategic advantage of fostering long-term supplier partnerships.
• Continuous monitoring of the patent landscape and global regulatory changes is essential for proactive risk management and ensuring supply chain resilience.

FAQs

1. What is the typical lead time for securing a significant quantity of dofetilide API from a new supplier? Lead times can vary widely, but typically range from 3 to 9 months, depending on the supplier's current production schedule, the required quantity, and the onboarding process, which includes audits and initial batch qualifications.

2. Are there any APIs for dofetilide that are not produced under cGMP conditions? For use in finished pharmaceutical products intended for human use in regulated markets (e.g., US, EU), dofetilide API must be manufactured under current Good Manufacturing Practices (cGMP). APIs not manufactured to these standards are not suitable for pharmaceutical applications.

3. What are the primary quality attributes that must be meticulously controlled for dofetilide API? Critical quality attributes include high chemical purity, stringent control of related substances and process impurities (especially genotoxic impurities), enantiomeric purity, particle size distribution, and polymorphic form, all of which impact the stability and bioavailability of the final drug product.

4. How can a company mitigate the risk associated with a single geographical concentration of dofetilide API manufacturers? Risk mitigation strategies include qualifying multiple suppliers in different geographical locations if feasible, maintaining strategic safety stock levels, and developing strong relationships with logistics providers to ensure swift rerouting capabilities in case of localized disruptions.

5. What is the role of a Drug Master File (DMF) in dofetilide API sourcing? A DMF is a submission to regulatory authorities (like the FDA) providing confidential, detailed information about the API's manufacturing process, facilities, and quality control. Finished drug product manufacturers reference this DMF in their applications, allowing regulators to review the API's quality without the API manufacturer disclosing proprietary information to the drug product manufacturer.

Citations

[1] Teva Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [relevant Teva API information, if publicly available, or general corporate site] [2] Hetero Drugs Limited. (n.d.). APIs. Retrieved from [relevant Hetero API information, if publicly available, or general corporate site] [3] Lupin Limited. (n.d.). API Business. Retrieved from [relevant Lupin API information, if publicly available, or general corporate site] [4] Divi's Laboratories Limited. (n.d.). APIs. Retrieved from [relevant Divi's Laboratories API information, if publicly available, or general corporate site] [5] Nectar Lifesciences Limited. (n.d.). Active Pharmaceutical Ingredients (APIs). Retrieved from [relevant Nectar Lifesciences API information, if publicly available, or general corporate site] [6] U.S. Food and Drug Administration. (n.d.). Guidance for Industry Drug Master Files. Retrieved from [FDA website for DMF guidance] [7] European Medicines Agency. (n.d.). Active substances (APIs). Retrieved from [EMA website for API information] [8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [ICH website for Q7 guideline]